Prime Discoveries is a leader in analyzing gut bacteria on an individualized basis. Its technology can collect and examine individual samples, store and correlate individual data, predict the outcomes of different potential treatments, and design new individually tailored drugs based on those predictions.
This technology is of major interest to the pharmaceutical industry because the presence or absence of certain gut bacteria are symptoms or causes of diabetes, cancer, and many infectious and autoimmune diseases. Thus, pharmaceutical companies who possess an understanding of the gut microbiome can surpass their competitors at diagnosing and treating many of the world’s most common and serious diseases.
Prime Discoveries has already signed $100 million+ customer contracts with half of all the pharmaceutical companies in this space; each of the rest has expressed interest. We anticipate a quick route to profitability and exit.
Zoic Investment Memo:
Zoic Value Add:
Expanding IP coverage for additional uses of applications as well as finding major pharmaceutical customers; especially internationally.
Pre-seed round committed: $1MM
Seed Round: $2MM
Expected Financial Terms:
Capital Investment: $500k
Participation Rights: Standard
Valuation Cap: $20MM
Form of Investment: Convertible Note
Board Position: One seat held by Zoic
Licensing and acquisition by pharmaceutical industry
Continue to generate revenue as an independent entity, especially as 5 contracts have already been signed with major pharmaceutical companies